Anomer Bio

Anomer Bio is exploring a new way of treating disease by focusing not on proteins, but on glycans: the sugars on the surface of cells that play a central role in how the body responds to disease. While most current therapies focus on proteins, Anomer Bio aims to stop cells from producing disease-driving glycans, opening a novel therapeutic avenue that could benefit a wide range of conditions.

The company is co-founded by Sophie James, CEO, and Marcos Burger Ramos, CSO, who are now working from SBC during the next phase of their development.